A randomized Phase III trial of neoadjuvant recombinant human endostatin, docetaxel and epirubicin as first‐line therapy for patients with breast cancer (<scp>CBCRT</scp>01)
Jianghao Chen(Zero to Three), Ling Wang(Xijing Hospital), Xiaodong Zhou(Xijing Hospital), Meiling Huang(Chongqing Medical University), Jing Wang(Ruijin Hospital), Ting Wang(Xijing Hospital), Qing Yao(Tianjin Meteorological Bureau), Yi Huan(Fujian Medical University), Bo Wang(Qilu Hospital of Shandong University), Juliang Zhang(Xijing Hospital), Yu Ming(Xijing Hospital), Qianxin Jia(Xijing Hospital)
Cited by 30
Related Papers
Prevalence of depressive disorders and treatment in China: a cross-sectional epidemiological study
|The Lancet Psychiatry|2021|826
Global burden of metabolic diseases, 1990–2021
|Metabolism|2024|294
Resveratrol‐enhanced autophagic flux ameliorates myocardial oxidative stress injury in diabetic mice
|Journal of Cellular and Molecular Medicine|2014|225
Health benefits of qigong or tai chi for cancer patients: a systematic review and meta-analyses
|Complementary Therapies in Medicine|2013|209
Characteristics of carbonaceous aerosol in the region of Beijing, Tianjin, and Hebei, China
|Atmospheric Environment|2013|190